Article
Correlation Between Platelet Indices and Residual Cancer Burden Score in Patients with Locally Advanced Luminal B HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
2026-07-21
Abstract excerpt
<title>Abstract</title> <p>Background Luminal B HER2-negative breast cancer often shows an incomplete pathological response after neoadjuvant chemotherapy. Residual Cancer Burden (RCB) is a standardized histopathological tool used to quantify post-treatment residual disease and has prognostic value after neoadjuvant therapy. Platelets interact with tumor cells through inflammatory, angiogenic, and metastatic pat...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- cb7af0d7-1742-5cc6-b5a3-0a670c9dfef1
- DOI
- 10.21203/rs.3.rs-10310233/v1
